| Objectives:To observe the efficacy and safety of liraglutide in elderly patients with type 2 diabetes mellitus and obesity,as well as the changes of adiponectin and resistin in peripheral blood before and after treatment,and to explore its application prospects and related mechanisms in elderly patients with diabetes mellitus and obesity.Methods:Fifty elderly patients with type 2 diabetes mellitus and obesity,49 elderly patients with type 2 diabetes mellitus and 49 elderly patients with obesity and 50 elderly patients with obesity and non-diabetes mellitus,and 48 elderly patients with non-obesity and non-diabetes mellitus in the physical examination center of our hospital were randomly selected from January to December 2018.The changes of adiponectin,resistin,blood sugar and islet function in elderly patients with type 2 diabetes mellitus and obesity were observed and compared.(2)Then 50 elderly patients with type 2 diabetes mellitus and obesity were randomly divided into control group(routine treatment)and observation group(liraglutide + routine treatment).After 3 months of treatment,the changes of each index and adverse drug reactions before and after treatment were compared.Results:1.There were no significant differences in general data(gender,age,course of disease,etc.)among the four groups(P > 0.05).Compared with the elderly non-obese non-diabetic group and the elderly obese non-diabetic group,the FBG,2hPBG and HbA1 c blood sugar levels in the elderly non-obese type 2 diabetic group,the elderly obese type 2 diabetic group increased(P < 0.05),and there was no difference in FBG,2hPBG,HbA1 c between the elderly non-obese type 2 diabetic group and the elderly obese type 2 diabetic group(P > 0.05).Compared with non-obese and non-diabetic elderly group and obese and non-diabetic elderly group,the levels of FCP and 2hCP in non-obese type 2 diabetic elderly group and obese type 2 diabetic elderly group decreased(P < 0.05).There was no difference in the levels of FCP and 2hCP between elderly non-obese type 2 diabetes mellitus group and elderly obese type 2 diabetes mellitus group.Compared with the elderly non-obese non-diabetic group,the levels of adiponectin in the elderly obese non-diabetic group,the elderly non-obese type 2 diabetic group and the elderly obese type 2 diabetic group decreased(P < 0.05),The level of adiponectin increased(P < 0.05);compared with the obese non-diabetic group and the elderly non-obese type 2 diabetic group,the adiponectin decreased more significantly in the obese type 2 diabetic group(P < 0.05),and the resistin increased more significantly(P < 0.05).2.After 3 months of treatment,FBG,2hPBG and HbA1 c in the observation group and the control group decreased compared with those before treatment(P < 0.05).There was no difference in FBG,2hPBG and HbA1 c between the observation group and the control group after treatment(P > 0.05).Compared with before treatment and control group,FC-P and 2hC-P in observation group increased(P < 0.05).Compared with before treatment and the control group,the blood lipid indexes TG,TC and LDL-C in the observation group decreased(all P < 0.05),while HDL-C did not change significantly(P > 0.05).Compared with before treatment and control group,BMI and waist circumference of observation group decreased significantly(P < 0.05).Compared with before treatment and control group,adiponectin in observation group increased(P < 0.05),resistin decreased(P < 0.05),while adiponectin and resistin in control group did not change significantly(P > 0.05).3.During the treatment period,the incidence of hypoglycemia in the observation group was lower than that in the control group(P < 0.05).There was no significant difference in gastrointestinal reactions between the observation group and the control group(P > 0.05).Conclusion:1.The level of serum adiponectin and C-peptide decreased and the level of serum resistin increased in the elderly patients with type 2 diabetes mellitus and obesity,suggesting that the function of islets decreased in different degrees.2.Liraglutide can significantly reduce the body weight,BMI,waist circumference,blood sugar,HbA1 c and TG,TC,LDL-C levels in elderly patients with type 2 diabetes mellitus and obesity,and increase the level of serum C-peptide.3.Liraglutide can reduce TG,TC,LDL-C and increase the level of serum C-peptide in elderly patients with type 2 diabetes mellitus complicated with obesity,which may be related to the increase of serum adiponectin level and the decrease of resistin level in elderly patients with type 2 diabetes mellitus complicated with obesity after treatment,and protect the function of islet cells.4.Liraglutide does not increase adverse drug reactions in elderly patients with type 2 diabetes mellitus and obesity. |
PDF Full Text Request